Lundbeck to Research Link Between Immune System and Brain Diseases
H. Lundbeck A/S (Lundbeck) is involved in new research that will investigate a novel link that could show a relationship between the immune system and mood disorders, such as depression, and neurodegenerative diseases, such as Alzheimer's disease. This project, a public-private partnership also involving The Wellcome Trust, Cambridge University and pharmaceutical company Janssen, may be the first step towards a new and significantly improved treatment for a broad range of brain diseases.
The main theory that the project will investigate is that the immune system can worsen brain diseases like depression and Alzheimer's disease. An imbalance in the immune system of the brain can drive a permanent and unhealthy neuro-inflammation — or inflammation in the brain — that can contribute to or cause brain diseases. Another sub-theory for investigation is that the immune system can improve brain diseases if it is triggered in the right way.
The initial link between the immune system and brain diseases has been established by a number of studies, which show that for some sub-groups of patients anti-inflammatory drugs have a positive effect. Some research indicates the presence of increased inflammatory cells and substances in brains of patients, and that anti-inflammatory drugs could decrease depressive symptoms without increasing the risks of adverse effects. This is interesting because a large number of patients today are still not receiving adequate treatment with the existing drugs. However, why and how some patients seem to benefit from receiving certain anti-inflammatory drugs is unclear and that is part of what this project will investigate.
"Neuro-inflammation has been increasingly implicated as a key player in a wide range of brain disorders including depression and Alzheimer's disease. This partnership is an exciting opportunity for us to increase our understanding of the important role of emerging immune and neuronal interactions in these disorders. We believe it can point us toward new avenues to develop breakthrough treatments for the patients," says Dr Stevin Zorn, EVP Lundbeck Research USA.
Related News
-
News CPHI Podcast Series: The power of proteins in antibody drug development
In the latest episode of the CPHI Podcast Series, Lucy Chard is joined by Thomas Cornell from Abzena to discuss protein engineering for drug design and development. -
News Amgen sues Samsung biologics unit over biosimilar for bone disease
Samsung Bioepis, the biologics unit of Samsung, has been issued a lawsuit brought forth by Amgen over proposed biosimilars of Amgen’s bone drugs Prolia and Xgeva. -
News CPHI Podcast Series: Why we need to consider women in clinical trials
The latest episode of the CPHI Podcast Series with Lucy Chard covers women's health, specifically women's representation in clinical trials, the associated bias, and the impacts on health for this population. -
News US FDA does not approve MDMA therapy for PTSD, requests more data
The MDMA-based therapeutic developed by Lykos Therapeutics, a California-based Public Benefit Corporation (PBC), has been reviewed and unapproved by the US FDA. The regulator has requested additional phase III trial data for further safety and efficacy... -
News Novartis and Viatris latest facing lawsuit over HeLa cell misuse
Global pharmaceutical companies Novartis and Viatris are the latest hit with a lawsuit claim pertaining to alleged misuse of the ‘HeLa’ cell line from the estate of woman whose cancerous tissue cells were taken without consent. -
News Sanofi invests billions into Frankfurt insulin production site
French pharmaceutical company Sanofi have announced an investment of EUR1.3 billion at their existing BioCampus site in Frankfurt am Main for the expansion of insulin production. -
News Novel oral Type 1 diabetes drug gains US FDA IND designation
A University of Alabama at Birmingham startup has gained FDA clearance for Investigational New Drug clinical trials for an oral Type 1 diabetes drug, a milestone for diabetes treatment. -
News A Day in the Life of a Vice President in R&D & Engineering
In the Day in the Life of Series, we've already had the chance to get to know a range of people in various roles in the pharma industry. In the latest interview we get a glimpse into the R&D side of things from Jennifer Sorrells, Vice Presiden...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance